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a new silver-triclosan vs a silver collagen-coated
polyester vascular graft against methicillin-resistant
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Ojan Assadian, MD,c Poitiers, France; and Vienna, Austria
Objectives:Vascular graft infection is a rare but serious complication of vascular reconstructive surgery. This in vitro study
investigated the antimicrobial efficacy of a new, silver-triclosan collagen-coated polyester vascular graft compared with a
silver collagen-coated polyester vascular graft alone during the first 24 hours.
Methods: The antimicrobial efficacy of the investigated vascular grafts was assessed by performing a time-kill kinetic assay
following Clinical and Laboratory Institute Standards-approved guidelines M26-A. For the purpose of the experimental
study, the ATCC 33591 strain of methicillin-resistant Staphylococcus aureus (American Type Culture Collection,
Manassas, Va) was used. All assays were repeated sixfold. Bacterial survival numbers were obtained at 1, 4, 8, 12, and 24
hours using a standard plate count procedure. Bactericidal activity was defined as a 3 log10 reduction factor (logRF),
according to the approved guideline M26-A.
Results: Both antimicrobial vascular grafts achieved >3 logRF and fulfilled the efficacy criterion for bactericidal activity
but performed differently in their speed of antimicrobial action. The silver-triclosan vascular graft achieved 3.37 logRF
after 8 hours, and the silver vascular graft showed a 4.19 logRF after 24 hours. The silver-triclosan graft yielded
significantly lower colony-forming units/mL counts after 4 hours compared with the silver graft (4.29  104 vs 1.03 
106; P  .031).
Conclusions: Both antimicrobial collagen-coated polymer vascular grafts showed bactericidal activity against methicillin-
resistant Staphylococcus aureus in vitro. Although the silver-triclosan vascular graft showed a faster antimicrobial efficacy,
the silver graft exhibited its antimicrobial properties after 24 hours. Which concept will protect an implanted vascular
prosthetic graft better from bacterial contamination and subsequent infection needs to be investigated further in in vivo
animal and clinical studies. ( J Vasc Surg 2012;55:823-9.)
Clinical Relevance: Vascular graft infection is a rare but one of the most serious complications of vascular reconstructive
surgery. Conservative treatment of prosthetic graft infections is rarely successful and is used only in patients with a high
operative risk or apparently limited infection. The most pre-eminent strategy against this severe complication therefore
is primary prevention of vascular graft infection. The use of antimicrobial vascular grafts might support prevention of
vascular graft infection. Results of a standardized experimental study on the antimicrobial efficacy of the silver-triclosan











dVascular graft infection is a rare but one of the most
serious complications of vascular reconstructive surgery.
The incidence of infection may vary from 0.5% to 6%,1-6
depending on the anatomic site, graft material, and pa-
tient’s comorbidities. For prosthetic vascular grafts, an
inverse correlation between the incidence of graft infection
and fatality of complications is generally observable. The
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f between 24% and 75% in affected patients.1,11,12
Although the optimal management and best surgical
reatment for infected vascular grafts remains controversial,
here is a general agreement that the most favorable results
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March 2012824 Ricco et alwill be achieved by early and complete removal of the
infected graft, with replacement using an in situ autologous
vein or an extra-anatomic prosthetic bypass.13-16 Conser-
vative treatment of prosthetic graft infections is rarely suc-
cessful and is used only in patients with a high operative risk
or apparently limited infection.12 It appears, therefore, that
the most pre-eminent strategy against this severe complica-
tion is primary prevention of vascular graft infection.
In vascular surgery, scientific evidence supporting the
efficacy of primary prevention of vascular graft infection is
scant. Although many are outdated, a number of studies
have investigated the utility of systemic prophylactic anti-
biotics in vascular surgery, and a variety of systemically
administrated antibiotics, singly or in combination, have
been proposed.17-20 Only a few studies have investigated
antimicrobial graft materials, predominantly containing
topical antibiotics and some using topical antiseptics. In
recent decades, various concepts for antimicrobial grafts
have been developed to prevent vascular graft infec-
tion.21-24 However, demonstration of the clinical efficacy
of antimicrobial graft material remains difficult because of
the low incidence of vascular graft infection.
In vitro studies are therefore necessary to evaluate and
compare these concepts, preferably under the same test
conditions and test methodology. We describe the charac-
teristics of a new antimicrobial polyester vascular graft that
combines two topical antiseptic agents, silver acetate and
triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol). The
aim of this in vitro experimental study was to compare the
antimicrobial efficacy of the silver-triclosan collagen poly-
ester vascular graft with an identical collagen polyester
vascular graft containing silver alone. A non-antimicrobial
collagen polyester vascular graft served as control.
METHODS
This study was planned and conducted between Sep-
tember 2010 and October 2010. All tests were performed
by NAMSA, an independent laboratory (North American
Science Associates, Inc, Northwood, Ohio), following a
predetermined study design.
Two antimicrobial vascular grafts and one non-
antimicrobial vascular graft were investigated. The three
vascular grafts were from MAQUET (La Ciotat, France):
(1) a silver-triclosan collagen-coated polyester vascular
Table I. Growth of methicillin-resistant Staphylococcus aur




Control 3.06  106  1.23  102
IGK 2.06  106  9.83  104
IGS 1.53  106  6.84  105
IGST 1.30  106  6.67  104
IGK, Non-antimicrobial InterGard vascular graft; IGS, InterGard Silver vas
aData are shown as colony-forming units/mL.graft (InterGard Synergy), containing the antiseptic agents ailver acetate and triclosan; (2) a silver collagen-coated poly-
ster vascular graft (InterGard Silver), containing silver acetate
lone; and (3) a non-antimicrobial collagen coated polyester
ascular graft (InterGard), serving as the control.
Test organism. For the purpose of the experimental
tudy, the ATCC 33591 (American Type Culture Collection,
anassas, Va) strain ofmethicillin-resistant Staphylococcus aureus
MRSA) was used because S aureus is the most commonly
eported pathogen responsible for vascular graft infection,25-29
nd the presence of amec A gene counteracts clinical efficacy
f perioperative antibiotic prophylaxis with all -lactam
ntibiotics.
Test procedure for assessing antimicrobial efficacy.
he antimicrobial efficacy of the investigated vascular grafts
as assessed under static contact conditions, and time-kill
ssays were performed according to the standard test
ethod M26-A recommended by the Clinical and Labora-
ory Institute Standards (CLIS).30,31
Briefly, a bacterial suspension was prepared by suspend-
ng a loopful of MRSA ATCC 33591 colonies in 9 mL of
rain-heart infusion broth, which was incubated at 37° 
°C for 18 to 24 hours. The density of the MRSA target
noculum was set at 1.0  107 colony-forming units
CFU)/mL. Standard plate count on trypticase-soy agar
lates was performed to determine the initial population of
he test organisms.
To reach a power of 80%, six repeated measures of
ach test sample for each interval (1, 4, 8, 12, and 24
ours) were placed on sterile 60-  15-mm Petri dishes.
he small Petri dishes were placed individually into larger
etri dishes (100  15 mm) containing 10 mL of sterile
ater to create a humid environment.
Each test graft was aseptically cut into 20-  20-mm
ieces and placed with the outer surface facing up in the
maller Petri dish. For the vascular grafts, five sets of six
epeated assays each were inoculated with 0.1 mL of the
RSA suspension and tested at static conditions incubated
or 1, 4, 8, 12, and 24 hours in an incubator at 37° 2°C.
ive sets of six repeated assays each of MRSA suspensions
ithout any test graft were prepared to serve as positive
ontrols. Immediately (zero time, data not shown) and at
he selected intervals, which were chosen to investigate the
ntimicrobial efficacy during the simulated immediate post-
perative interval of 1 to 24 hours, aliquots were removed
s shown for three vascular grafts—two antimicrobial and
without any graft material (control)a
4 hours
0 Mean  SE Log10
6.27  106  3.32  103 6.80
1.84  106  2.37  105 6.26
1.03  106  1.86  105 6.01
4.29  104  6.90  103 4.63
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Volume 55, Number 3 Ricco et al 825prepared in-house by the NAMSA laboratory, and mixed
for 1minute using a vortex. Bacterial survival numbers were
obtained by removing 0.1-mL samples of broth, and sub-
sequent viable counts were determined at 1, 4, 8, 12, and
24 hours using a standard plate count procedure.
Statistical analysis. To determine the required num-
ber of repeated measurements for each graft at each of the
five assessment times (1, 4, 8, 12, and 24 hours), a power
analysis using a one-way analysis of variance (ANOVA) was
performed. For a significance level of .05, we set the effect
size of the antimicrobial grafts at a moderate   2.0,
assuming that an antimicrobial graft will show at least a
double decrease in the numbers of test bacteria. Using this
conservative assumption, a sixfold repeated measure of
each time point reached a power of 80.5%. Therefore, all
assays were repeated six times, and the numbers of
organisms were averaged as the mean CFU/mL. The
averaged means were then transformed and expressed as
mean log10 CFU/mL.
To present the data in the format of a “time-kill curve,”
the obtained viable mean log10 counts (CFU/mL) at each
investigated time point were plotted for each graft and the
control without graft against time (1, 4, 8, 12, and 24
hours). Following the approved guideline CLIS M-26A,30
bactericidal activity was defined as a 3 log10 reduction in
CFU/mL, and bacteriostatic activity was defined as a 3
log10 reduction in CFU/mL. The lower limit of detection
was 2.0 log10 CFU/mL. The log10 reduction factor
(logRF) was calculated as log10 of the incubated inoculum
without a graft minus log10 of the respective vascular grafts
(InterGard, InterGard Silver, or InterGard Synergy) at each
time point.
For determining a statistical significant difference be-
tween the mean log10 CFU/mL counts of two grafts or
one graft and the control without any graft material at
single time point, a nonparametric Wilcoxon signed-rank
test was calculated. To calculate one graft’s overall differ-
ence in the mean log10 CFU/mL over the five tested time
points, a one-way ANOVA was separately calculated for
each graft. To compare two grafts (InterGard vs InterGard
Silver; InterGard vs InterGard Synergy; and InterGard
Silver vs InterGard Synergy) over all tested time points, a
two-way ANOVA was computed. To minimize a type I
error, one-way and two-way ANOVA were calculated with




Mean  SE Log10 M
Control 2.35  107  2.74  103 7.37 3.20  1
IGK 2.30  106  2.65  105 6.36 2.64  1
IGS 4.27  105  1.19  105 5.63 3.75  1
IGST 9.96  103  7.52  103 4.00 1.58  1P  .05 was considered statistically significant. WESULTS
The mean CFU/mL, together with standard error and
he corresponding log10 transformations of the time-kill
tudy, are summarized in Table I and plotted as time-kill
urves in the Fig. As expected, no antibacterial activity was
een the incubated inoculum without any graft material
control; P  .0964, one-way ANOVA) and the non-
ntimicrobial collagen-coated polyester vascular graft
InterGard). The control curve (Fig) showed a typical
rowth curve for incubated bacteria in cultivation medium.
he non-antimicrobial graft showed no increase, but also
o decrease, in the number of viable organisms at the five
ime points during 24 hours of incubation (P  .0798
ne-way ANOVA).
The antimicrobial vascular grafts both achieved 3
ogRF and fulfilled the efficacy criterion for bactericidal
ctivity; yet, they performed differently in their speed of
ntimicrobial action. The silver-triclosan vascular graft
InterGard Synergy) exhibited a mean 3.37 logRF after 8
ours, and the silver vascular graft (InterGard Silver)
howed a mean 4.19 logRF after 24 hours of incubation
Table II) compared with the non-antimicrobial graft.
For the InterGard Silver graft, one-way ANOVA with
onferroni correction showed a significant difference over
ime (P  .0224; F  3.45; df 4) with a significance
etween all five time points from 1 to 24 hours; for the
nterGard Synergy, the difference was also significant (P 
0001; F 362.44; df4; one-way ANOVA with Bonfer-
oni correction) with significant differences between 1 vs 4
ours, 1 vs 8 hours, 1 vs 12 hours, and 1 vs 24 hours.
InterGard Silver yielded significantly lower mean
FU/mL counts at 24 hours than the non-antimicrobial
ontrol graft (1.04  104 vs 6.47  105; P  .031
ilcoxon rank-sum test). InterGard Synergy, however,
chieved significant lower mean CFU/mL counts than the
on-antimicrobial control graft already at 4 hours of incu-
ation (4.29  104 vs 1.84  106; P  .031 Wilcoxon-
ank-sum test).
Comparing the two antimicrobial vascular grafts,
nterGard Synergy yielded significantly lower mean
FU/mL counts at 4 hours vs InterGard Silver (4.29 
04 vs 1.03 106; P .031 Wilcoxon rank-sum test), but
ot at 1 hour (1.30  106 vs 1.53  106; P  .437
12 hours 24 hours
SE Log10 Mean  SE Log10
5.42  102 7.51 1.60  108  3.53  103 8.20
9.83  105 6.42 6.47  105  2.67  105 5.81
9.16  104 5.57 1.04  104  4.97  103 4.02
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The silver vascular graft and the silver-triclosan vascular
graft both showed bactericidal efficacy against MRSA in this
standard in vitro method. There was, however, a difference
in the time when the antimicrobial efficacy reached 3
logRF. Although the silver-triclosan vascular graft exhib-
ited 3.37 logRF after 8 hours, the silver vascular graft
Fig. Time-kill curve of two antimicrobial (InterGard
large-dashed line, circle) vascular grafts and one non-antim
against methicillin-resistant Staphylococcus aureus (MRS
incubation. The mean colony-forming units/mL count
rhombus) without any graft material shows the typical gr
Table II. Mean log10 reduction factors as the difference
in means from three grafts—two antimicrobial and one
nonantimicrobial—compared with the incubated
inoculum without graft material (control)
Variable 1 h 4 h 8 h 12 h 24 h
IGK 0.17 0.53 1.01 1.08 2.39
IGS 0.30 0.78 1.74 1.93 4.19a
IGST 0.37 2.16 3.37a 5.31a 6.20a
IGK, Non-antimicrobial InterGard vascular graft; IGS, InterGard Silver
vascular graft; IGST, InterGard Silver/triclosan vascular graft.
aBactericidal efficacy at each exposure time as defined by approved guideline
Clinical and Laboratory Institute Standards M-26A, 1999.30achieved 3 logRF only after 24 hours. hBecause both collagen-coated polyester vascular grafts
re manufactured under the same standards and differ only
n the presence or absence of triclosan, the observed differ-
nce in the antimicrobial efficacy is explained only by the
dditional antimicrobial activity of triclosan. The addition
f triclosan to the already-existing silver collagen-coated
olyester graft has microbiologic advantages.
The silver mode of action has already been described in
etails elsewhere.24 Although the antimicrobial efficacy of
ilver covers a broad microbial spectrum, its mode of action
s not as fast as triclosan, as was shown in the present study.
ilver needs longer contact times with possible pathogens
ndwill exhibit its antimicrobial properties only over longer
eriods. Furthermore, silver is released more slowly from
he graft material than triclosan.
Triclosan alone, on the other hand, would be the ideal
ntiseptic to be used for coating vascular grafts because it is
oxicologically safe and has a rapid antimicrobial ac-
ion.32-34 Triclosan, however, leaches rapidly from the graft
aterial into the surrounding tissue and will be metabo-
ized in the liver, principally by phase II metabolism, to
lucuronide and sulfate conjugates that have an elimination
[IGS]; solid line, square; InterGard Synergy [IGST];
ial (InterGard [IGK] dotted line, triangle) vascular graft
rowth without graft material during 4 to 24 hours of
RSA are shown. The control curve (small-dashed line,
curve for incubated bacteria in cultivation medium.Silver
icrob
A) g
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with broad, antimicrobial properties. It is lipophilic and
active within a broad pH range (optimum pH, 4-8) unlike
other antiseptics that become inactive at high or low pH.
Triclosan passively dissipates from implanted grafts to
the surrounding tissues, where it is absorbed into the
bloodstream and widely distributed, but it is not confined
to any particular tissue or organ system. After one exposure,
triclosan is cleared from the bloodstream in 3.8 days.
Conjugated triclosan is readily water soluble and is excreted
from the body by the kidneys.36 Combining silver acetate
with triclosan compensates for their respective pharmaco-
kinetic disadvantages in time of action and duration, and a
faster and prolonged antimicrobial activity is achieved.
Triclosan is present in some medical products and in a
broad range of consumer products. In health care, triclosan
is used in medicated soap and skin antiseptics at concentra-
tions of 0.2% to 0.5% and up to 3%, respectively, in oint-
ments and impregnated/coated medical devices such as
catheters and surgical sutures. Aside from its medical used,
such as for decolonization of MRSA carriers or preven-
tion of medical device contamination and implant infec-
tion, triclosan is used in a surprisingly extensive range of
consumer, personal health care, and household prod-
ucts, which is in some cases questionable (eg, kitchenware
and dishwashing liquids) and in others is frivolous and
unnecessary (eg, dogs’ drinking bowls or antimicrobial
underwear).
The consequences of this widespread, unregulated use
of triclosan, allied with marketing that plays to consumer
fears, has spurred critical comment in lay and professional
media and has driven scepticism and mistrust about its use.
It has also provoked calls for a wider analysis of the health
and environmental issues associated with overuse of tri-
closan,37 particularly in Northern European countries. The
interest has focused on potential health concerns associated
with triclosan side products released to the environment
during the breakdown of triclosan, which, however, occurs
in nature only in certain situations, such as presence of UV
light, but never in the human body. Potentially harmful
side products include chloroform gas (CHCl3), which may
be produced by the reaction of triclosan and chlorine in tap
water. Chloroform is classified by the EPA as a probable
carcinogenic compound37 and has been shown to cause
hepatocellular carcinoma in rats. Chloroform is also toxic at
high doses (fatal oral dose, 10 mL [14.8 g]; death due to
respiratory or cardiac arrest).
In thepresenceof hydrogen chloride, triclosan can also form
the dioxin 2,4-dichlorophenol (a chlorinated derivative of phe-
nol). However, this reaction occurs only in presence of UV
radiation. Themeremention of dioxins alarmsmany people, but
of 210 known dioxins, only 17 are harmful. The most toxic
dioxin is2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),which is
not formed with triclosan.
Calls for the restriction of triclosan use are justified in
context with the increase of triclosan in a wide range of
consumer products. However, if the use of triclosan is associ-
ated with demonstrable health benefits, such as in medical ipplications for the prevention or treatment of infection, its
se should be considered and shall be distinguished from
ndications with no plausible or proven benefit.
Although beneficial, the use of vascular prosthetic
rafts is correlated with an increased risk of infection,
orbidity, and death. This, however, is not only restricted
o vascular grafts but also applies to all implanted prosthetic
aterial. The risk for infection varies by medical specializa-
ion and medical device. Reported infection rates range
rom 1% to 6% after cardiac valve implantation, 0.5% to 6%
or vascular grafts, 10% to 30% for urinary catheters, 25% to
0% for aortic balloon pumps, 5% to 41% for neurosurgical
iquor shunts, and 1% to 20% for herniamesh implants.38-41
he morbidity associated with prosthetic graft infection is
igh. For peripheral vascular prostheses, morbidity of up to
1% has been reported, mostly resulting in amputation,
ogether with an attributable mortality rate of 17%. A
ortality rate of 24% to 75% was observed in patients with
ortic vascular grafts, with a 5-year survival rate50%.42,43
Prosthetic graft infection starts with contamination of
he graft and formation of biofilms.44,45 Biofilms result
rom microbial adhesion to surfaces in moist environments
nd can be found in virtually every environment with
ufficient provision of water and nutrients. Formation of a
iofilm begins with the attachment of planktonic microor-
anisms to a surface. The microbial attachment is initially
upported by reversible van der Waals forces and electro-
tatic bonds, dipole interactions, hydrogen bonds, and
ovalent bonds. If the attached organisms are not immedi-
tely separated from the surface or inactivated, they will
tart colonizing the surface permanently, supported by cell
dhesion structures and active, progressive movement.
ithin the formed biofilm, bacteria may communicate by
he release of signal molecules (“quorum sensing”) that
oordinate the formation of structured and stable biofilms.
nce colonization begins, the biofilm will grow by a com-
ination of cell division and by genesis of a matrix of
xcreted extracellular polymeric substance. This matrix
rotects the microorganisms embedded within the biofilm.
rom the microorganism’s perspective, one major benefit
f this matrix is the increased protection against the im-
une system and considerably decreased susceptibility to
ntiseptics and antibiotics. It is therefore desirable to min-
mize the formation of biofilms on medical implants or to
revent their formation completely.
Antimicrobial prosthetic grafts might limit coloniza-
ion by microorganisms, and this study provides quantita-
ive and objective results of the in vitro efficacy of two
ntimicrobial vascular grafts. However, we recognize that
ur study has some limitations. The study was designed to
ssess the antimicrobial efficacy within the immediate post-
perative period, defined as 24 hours; however, depending
f the product type, this time frame can be discussed. This
hoice was made considering that it is generally believed
hat most vascular graft infections have their origins in the
mmediate postoperative period. With this in mind, the
ilver collagen and silver triclosan grafts were designed for
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antimicrobial agents up to 30 days. Whether this is suffi-
cient in current clinical practice to prevent vascular graft
infections is unknown.
Furthermore, the in vitro tests applied here were per-
formed on planktonic bacterial suspensions and not on
established biofilms. Considering that this experimental
work aimed to assess antimicrobial efficacy during the
immediate postoperative period, the use of planktonic cul-
ture is relevant because biofilms require a longer time to
develop. However, on a longer time scale, some bacterial
species may initiate biofilm formation for protection against
the environment. Biofilms are less susceptible to antimicro-
bial agents because the bacteria are protected by the extra-
cellular polymeric substance.44,45 This aspect should also
be addressed when assessing long-term antimicrobial effi-
cacy in future experiments.
Finally, this study tested the antimicrobial efficacy
against one MRSA strain only. Therefore, our conclusions
are valid only for Gram-positive cocci, but no statement can
bemade about Gram-negative and -positive bacteria. How-
ever, because S aureus is the most common pathogen
causative for vascular graft infection25-29 and methicillin
resistance is rapidly increasing worldwide,46 preventing S
aureus vascular graft infections is of particular relevance.
CONCLUSIONS
The two antimicrobial collagen-coated polymer vascu-
lar grafts showed bactericidal activity against MRSA in
vitro. The silver-triclosan vascular graft showed faster anti-
microbial efficacy, and the silver graft exhibited its antimi-
crobial properties after 24 hours. It remains unknown if this
concept will protect an implanted vascular prosthesis better
from bacterial contamination and infection. This aspect
needs to be investigated further in in vivo animal and
clinical studies.
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